MTOR and prostate carcinoma: One group designed a novel dendrimer conjugated to the mTOR inhibitor rapamycin to successfully inhibit mTOR signalling and VEGF expression in prostate cancer cells and fibroblasts, and reduce fibroblast-mediated prostate tumour progression and metastasis.92 Another group targeted neuregulin (NRG1), which is highly expressed in the cancer cells and CAFs of PDAC.